Drugs & Targets FDA grants priority review for NDA of asciminib in CML indication September 03, 2021Vol.47 No.32
Drugs & Targets European Commission approves Minjuvi + lenalidomide for relapsed/refractory DLBCL September 03, 2021Vol.47 No.32
Drugs & Targets EMA validates application for Opdivo + Yervoy and Opdivo + chemotherapy in recurrent or metastatic ESCC indication September 03, 2021Vol.47 No.32
Drugs & Targets Sabatolimab receives orphan drug designation from the European Commission for myelodysplastic syndromes September 03, 2021Vol.47 No.32
Drugs & Targets Foundation Medicine and Epic to streamline access to genomic testing for precision cancer care September 03, 2021Vol.47 No.32
Drugs & Targets Werewolf Therapeutics, Merck collaborate on WTX-124 INDUKINE Program September 03, 2021Vol.47 No.32
The Hutch, University of Washington, and Seattle Children’s forming a more streamlined union July 16, 2021Vol.47 No.28By Paul Goldberg
Cancer History ProjectConversation with The Cancer Letter How Fred Hutch, UW and Seattle Children’s helped revive NCI-designated consortium cancer centers July 16, 2021Vol.47 No.28By Paul Goldberg
